# A Study to Provide Continued Access to Mitapivat for Participants Who Previously Completed an Agios-Sponsored Mitapivat Study

> **NCT05777993** · PHASE4 · ENROLLING_BY_INVITATION · sponsor: **Agios Pharmaceuticals, Inc.** · enrollment: 6 (estimated)

## Conditions studied

- Pyruvate Kinase Deficiency
- Anemia, Hemolytic

## Interventions

- **DRUG:** Mitapivat

## Key facts

- **NCT ID:** NCT05777993
- **Lead sponsor:** Agios Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2023-07-06
- **Primary completion:** 2029-08
- **Final completion:** 2029-08
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05777993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05777993, "A Study to Provide Continued Access to Mitapivat for Participants Who Previously Completed an Agios-Sponsored Mitapivat Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05777993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*